3-(2,4-Dimethoxybenzylidene)-anabaseine: A promising candidate drug for Alzheimer's disease?

Geriatrics and Gerontology International

Volumn 12, Issue 3, 2012, Pages 365-371

  Zawieja, Philippe ^a   Kornprobst, Jean Michel ^b   Métais, Patrick ^c  

^a PSL RESEARCH UNIVERSITY   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Health Luxembourg Invest SA Luxembourg   (Luxembourg)

Author keywords

Acetylcholinesterase inhibitors; Alzheimer's disease; Amyloid ; Anabaseine; Neuroinflammation

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; NATURAL PRODUCT; NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMPHIPORUS LACTIFLOREUS; HUMAN; NEMERTEA; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; BENZYLIDENE COMPOUNDS; HUMANS; NICOTINIC AGONISTS; PYRIDINES;

EID: 84862679888     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/j.1447-0594.2011.00827.x     Document Type: Review

References (73)

1. Ferri CP, Prince M, Brayne C etal. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117.
2. Wimo A, Prince M. World Alzheimer Report 2010 - The Global Economic Impact of Dementia. London: Alzheimer's Disease International (ADI) 2010.
3. Bi X. Alzheimer disease: update on basic mechanisms. JAOA 2010; 110 (9 Suppl 8): 3-9.
4. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010; 88 (4): 475-486.
5. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010; 9 (7): 702-716.
6. Potter PE. Investigational medications for treatment of patients with Alzheimer disease. J Am Osteopath Assoc 2010; 110 (9 Suppl 8): S27-S36.
7. Queen BL, Tollefsbol TO. Polyphenols and aging. Curr Aging Sci 2010; 3 (1): 34-42.
8. Di Stefano A, Iannitelli A, Laserra S, Sozio P. Drug delivery strategies for Alzheimer's disease treatment. Expert Opin Drug Deliv 2011; 8: 581-603. doi:10.1517/17425247.2011.561311.
9. Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA. Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med 2009; 13 (1): 61-86.
10. Holtzman JL. Are we prepared to deal with the Alzheimer's disease pandemic? Clin Pharmacol Ther 2010; 88 (4): 563-565.
11. Adrian TE. Novel marine-derived anti-cancer agents. Curr Pharm Des 2007; 13 (33): 3417-3426.
12. Barthomeuf C, Bourguet-Kondracki ML, Kornprobst JM. Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy. Anticancer Agents Med Chem 2008; 8 (8): 886-903.
13. Singh R, Sharma M, Joshi P, Rawat DS. Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med Chem 2008; 8 (6): 603-617.
14. Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov 2009; 8 (1): 69-85.
15. Farokhi F, Wielgosz-Collin G, Clement M, Kornprobst JM, Barnathan G. Cytotoxicity on human cancer cells of ophidiacerebrosides isolated from the African starfish Narcissia canariensis. Mar Drugs 2010; 8 (12): 2988-2998.
16. Bourguet-Kondracki ML, Kornprobst JM. Marine pharmacology: potentialities in the treatment of infectious diseases, osteoporosis and Alzheimer's disease. Adv Biochem Engin Biotechnol 2005; 97: 105-131.
17. Martinez A. Marine-derived drugs in neurology. Curr Opin Investig Drugs 2007; 8 (7): 525-530.
18. Kem WR. A study of the occurrence of anabaseine in Paranemertes and other nemertines. Toxicon 1971; 9: 23-32.
19. Kem WR, Scott KN, Duncan JH. Hoplonemertine worms: a new source of pyridine neurotoxins. Experientia 1976; 32: 684-686.
20. Wheeler JW, Olubajo O, Storm CB, Duffield RM. Anabaseine: venom alkaloid of Aphaenogaster ants. Science 1981; 211: 1051-1052.
21. Kem WR, Soti F. Amphiporus alkaloid multiplicity implies functional diversity: initial studies on crustacean pyridyl receptors. Hydrobiologia 2001; 456: 221-231.
22. Kem WR, Mahnir VM, Papke RL, Lingle CJ. Anabaseine is a potent agonist upon muscle and neuronal α-bungarotoxin sensitive nicotinic receptors. J Pharmacol Exp Ther 1997; 283: 979-992.
23. Leclercq S, Charles S, Daloze D, Breakman JC, Aron S, Pasteels JM. Absolute configuration of anabasine from Messor and Aphaenogaster ants. J Chem Ecol 2001; 27: 945-952.
24. Co JE, Jones TH, Hefetz A, Tinault A, Snelling RR. The comparative exocrine chemistry of nine Old World species of Messor (Formicidae: Myrmicinae). Biochem Syst Ecol 2003; 31: 367-373.
25. Cruz-Lopez L, Jackson BD, Hefetz A, Morgan DE. Alkaloids in the venom of Messor ants. Biochem Syst Ecol 2006; 34: 199-204.
26. Attygalle AB, Kern F, Huang Q, Meinwald J. Trail pheromone of the myrmicine ant Aphaenogaster rudis (Hymenoptera: Formicidae). Naturwissenschaften 1998; 85: 38-41.
27. Raspotnig G, Schaider M, Föttinger P, Komposch C, Karaman I. Nitrogen-containing compounds in the scent gland secretions of European cladonychiid harvestmen (Opiliones, Laniatores, Travunioidea). J Chem Ecol 2011; 37 (8): 912-921.
28. Machado G, Bonato V, Oliveira PS. Alarm communication: a new function for the scent gland secretion in harvestmen (Arachnida:Opiliones). Naturwissenschaften 2002; 89: 357-360.
29. Thollesson M, Norenburg JL. Ribbon worm relationships: a phylogeny of the phylum. Nemertea Proc Biol Sci 2003; 270: 407-415.
30. Kem WR, Soti F, Wildeboer K etal. The nemertine toxin anabaseine and its derivative DMXBA (GTS-21): chemical and pharmacological properties. Mar Drugs 2006; 4 (3): 255-273.
31. Whitehouse PJ, Martino AM, Antuono PG etal. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res 1986; 371: 146-151.
32. Newhouse PA, Potter A, Lenox RH. Effects of nicotinic agents on human cognition: possible therapeutic applications in Alzheimer's and Parkinson's diseases. Med Chem Res 1993; 2: 628-642.
33. DeFiebre CM, Meyer EM, Henry JC, Muraskin SI, Kem WR, Papke RL. Characterization of a series of anabaseine-derived compounds reveals that the 3-(4)-dimethylaminocinnamylidine derivative is a selective agonist at neuronal nicotinic alpha 7/125I-alpha-bungarotoxin receptor subtypes. Mol Pharmacol 1995; 47: 164-171.
34. Meyer EM, Tay ET, Papke RL, Meyers C, Huang GL, de Fiebre CM. [2, 4-dimethoxybenzylidene]anabaseine (DMXB) selectively activates rat α7 receptors and improves memory-related behaviors in a mecamylamine-sensitive manner. Brain Res 1997; 768: 49-56.
35. Kem WR. Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Invert Neurosci 1997; 3: 251-259.
36. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000; 113: 169-181.
37. Kem WR, Mahnir VM, Prokai L etal. Hydroxy metabolites of the Alzheimer's drug candidate 3-[(2, 4-dimethoxy)benzylidene]-anabaseine dihydrochloride (GTS-21): their molecular properties, interactions with brain nicotinic receptors, and brain penetration. Mol Pharmacol 2004; 65: 56-67.
38. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 1995; 674: 252-259.
39. Woodruff-Pak DS, Li YT, Kem WR. A nicotinic agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res 1994; 645: 309-317.
40. Briggs CA, Anderson DJ, Brioni JD etal. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol Biochem Behav 1997; 57: 231-241.
41. Chen L, Wang H, Zhang Z etal. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35)-injected mice through preventing the dysfunction of alpha7 nicotinic receptor. J Neurosci Res 2010; 88 (8): 1784-1794.
42. Stevens KE, Cornejo B, Adams CE etal. Continuous administration of a selective alpha7 nicotinic partial agonist, DMXBA, improves sensory inhibition without causing tachyphylaxis or receptor upregulation in DBA/2 mice. Brain Res 2010; 1352: 140-146.
43. Ren K, King MA, Liu J etal. The alpha7 nicotinic receptor agonist 4OH-GTS-21 protects axotomized septohippocampal cholinergic neurons in wild type but not amyloid-overexpressing transgenic mice. Neuroscience 2007; 148 (1): 230-237.
44. Van Haaren F, Anderson KG, Haworth SC, Kem WR. GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 1999; 64: 439-444.
45. Qi XL, Nordberg A, Xiu J, Guan ZZ. The consequences of reducing expression of the alpha7 nicotinic receptor by RNA interference and of stimulating its activity with an alpha7 agonist in SH-SY5Y cells indicate that this receptor plays a neuroprotective role in connection with the pathogenesis of Alzheimer's disease. Neurochem Int 2007; 51 (6-7): 377-383.
46. Stokes C, Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL. The structural basis for drug selectivity between human and rat nicotinic alpha7 receptors. Mol Pharmacol 2004; 66: 14-24.
47. Papke RL, Meyer E, Nutter T, Uteshev VV. Alpha7-selective agonists and modes of alpha7 receptor activation. Eur J Pharmacol 2000; 393: 179-195.
48. Li Y, Meyer EM, Walker DW, Millard WJ, He YJ, King MA. Alpha7 nicotinic receptor activation inhibits ethanol-induced mitochondrial dysfunction, cytochrome c release and neurotoxicity in primary rat hippocampal neuronal cultures. J Neurochem 2002; 81: 853-858.
49. Nai Q, McIntosh JM, Margiotta JF. Relating neuronal nicotinic acetylcholine receptor subtypes defined by subunit composition and channel function. Mol Pharmacol 2003; 63: 311-324.
50. Machu TK, Hamilton ME, Frye TF etal. Benzylidene analogs of anabaseine display partial agonist and antagonist properties at the mouse 5-hydroxytryptamine(3A) receptor. J Pharmacol Exp Ther 2001; 299: 1112-1119.
51. Kitagawa H, Takenouchi T, Azuma R etal. Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 2003; 28: 542-551.
52. Grønlien JH, Håkerud M, Ween H etal. Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 2007; 72 (3): 715-724.
53. Papke RL, Kem WR, Soti F, López-Hernández GY, Horenstein NA. Activation and desensitization of nicotinic alpha7-type acetylcholine receptors by benzylidene anabaseines and nicotine. J Pharmacol Exp Ther 2009; 329 (2): 791-807.
54. López-Hernández GY, Thinschmidt JS, Morain P etal. Positive modulation of alpha7 nAChR responses in rat hippocampal interneurons to full agonists and the alpha7-selective partial agonists, 4OH-GTS-21 and S 24795. Neuropharmacology 2009; 56 (4): 821-830.
55. Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berlin) 2004; 174 (1): 54-64.
56. Tregellas JR, Olincy A, Johnson L etal. Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia. Neuropsychopharmacology 2010; 35 (4): 938-942.
57. Olincy A, Harris JG, Johnson LL etal. Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 2006; 63: 630-638.
58. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007; 74 (8): 1192-1201.
59. Freedman R, Olincy A, Buchanan RW etal. Initial phase 2 trial of a nicotinic agonist in schizophrenia. Am J Psychiatry 2008; 165: 1040-1047.
60. Tregellas JR, Tanabe J, Rojas DC etal. Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia. Biol Psychiatry 2011; 69 (1): 7-11.
61. Desai RI, Bergman J. Drug discrimination in methamphetamine-trained rats: effects of cholinergic nicotinic compounds. J Pharmacol Exp Ther 2010; 335 (3): 807-816.
62. Rosas-Ballina M, Tracey KJ. Cholinergic control of inflammation. J Intern Med 2009; 265 (6): 663-679.
63. Kox M, van Velzen JF, Pompe JC, Hoedemaekers CW, van der Hoeven JG, Pickkers P. GTS-21 inhibits pro-inflammatory cytokine release independent of the Toll-like receptor stimulated via a transcriptional mechanism involving JAK2 activation. Biochem Pharmacol 2009; 78 (7): 863-872.
64. Pavlov VA, Ochani M, Yang LH etal. Selective α7 nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 2007; 35: 1139-1144.
65. Rosas-Ballina M, Goldstein RS, Gallowitsch-Puerta M etal. The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and RAGE. Mol Med 2009; 15: 195-202.
66. Bruchfeld A, Goldstein RS, Chavan S etal. Whole blood cytokine attenuation by cholinergic agonists ex vivo and relationship to vagus nerve activity in rheumatoid arthritis. J Intern Med 2010; 268 (1): 94-101.
67. Schlachetzki JC, Hüll M. Microglial activation in Alzheimer's disease. Curr Alzheimer Res 2009; 6 (6): 554-563.
68. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 2010; 16 (25): 2766-2778.
69. McGeer EG, McGeer PL. Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis 2010; 19 (1): 355-361.
70. Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA. Neuroinflammation - an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener Dis 2010; 7 (1-3): 38-41.
71. McNaull BB, Todd S, McGuinness B, Passmore AP. Inflammation and anti-inflammatory strategies for Alzheimer's disease- a mini-review. Gerontology 2010; 56 (1): 3-14.
72. Norman GJ, Morris JS, Karelina K etal. Cardiopulmonary arrest and resuscitation disrupts cholinergic anti-inflammatory processes: a role for cholinergic α7 nicotinic receptors. J Neurosci 2011; 31 (9): 3446-3452.
73. Metcalfe MJ, Figueiredo-Pereira ME. Relationship between tau pathology and neuroinflammation in Alzheimer's disease. Mt Sinai J Med 2010; 77 (1): 50-58.